392 related articles for article (PubMed ID: 28229514)
21. EZH2 mutation in an adolescent with Weaver syndrome developing acute myeloid leukemia and secondary hemophagocytic lymphohistiocytosis.
Usemann J; Ernst T; Schäfer V; Lehmberg K; Seeger K
Am J Med Genet A; 2016 May; 170A(5):1274-7. PubMed ID: 26762561
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
[TBL] [Abstract][Full Text] [Related]
23. Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.
Korfhage J; Lombard DB
Mol Cancer Res; 2019 Jul; 17(7):1417-1428. PubMed ID: 31023785
[TBL] [Abstract][Full Text] [Related]
24. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27.
Kirmizis A; Bartley SM; Kuzmichev A; Margueron R; Reinberg D; Green R; Farnham PJ
Genes Dev; 2004 Jul; 18(13):1592-605. PubMed ID: 15231737
[TBL] [Abstract][Full Text] [Related]
25. The polycomb group protein SUZ12 regulates histone H3 lysine 9 methylation and HP1 alpha distribution.
de la Cruz CC; Kirmizis A; Simon MD; Isono K; Koseki H; Panning B
Chromosome Res; 2007; 15(3):299-314. PubMed ID: 17406994
[TBL] [Abstract][Full Text] [Related]
26. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
[TBL] [Abstract][Full Text] [Related]
27. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z
BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081
[TBL] [Abstract][Full Text] [Related]
28. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex.
Cao R; Zhang Y
Mol Cell; 2004 Jul; 15(1):57-67. PubMed ID: 15225548
[TBL] [Abstract][Full Text] [Related]
29. Imagawa-Matsumoto syndrome: SUZ12-related overgrowth disorder.
Imagawa E; Seyama R; Aoi H; Uchiyama Y; Marcarini BG; Furquim I; Honjo RS; Bertola DR; Kim CA; Matsumoto N
Clin Genet; 2023 Apr; 103(4):383-391. PubMed ID: 36645289
[TBL] [Abstract][Full Text] [Related]
30. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
[TBL] [Abstract][Full Text] [Related]
31. Mutations in SETD2 cause a novel overgrowth condition.
Luscan A; Laurendeau I; Malan V; Francannet C; Odent S; Giuliano F; Lacombe D; Touraine R; Vidaud M; Pasmant E; Cormier-Daire V
J Med Genet; 2014 Aug; 51(8):512-7. PubMed ID: 24852293
[TBL] [Abstract][Full Text] [Related]
32. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
[TBL] [Abstract][Full Text] [Related]
33. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.
Khan SN; Jankowska AM; Mahfouz R; Dunbar AJ; Sugimoto Y; Hosono N; Hu Z; Cheriyath V; Vatolin S; Przychodzen B; Reu FJ; Saunthararajah Y; O'Keefe C; Sekeres MA; List AF; Moliterno AR; McDevitt MA; Maciejewski JP; Makishima H
Leukemia; 2013 Jun; 27(6):1301-9. PubMed ID: 23486531
[TBL] [Abstract][Full Text] [Related]
34. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
[TBL] [Abstract][Full Text] [Related]
35. Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.
Martin MC; Zeng G; Yu J; Schiltz GE
J Med Chem; 2020 Dec; 63(24):15344-15370. PubMed ID: 33283516
[TBL] [Abstract][Full Text] [Related]
36. The JAZF1-SUZ12 fusion protein disrupts PRC2 complexes and impairs chromatin repression during human endometrial stromal tumorogenesis.
Ma X; Wang J; Wang J; Ma CX; Gao X; Patriub V; Sklar JL
Oncotarget; 2017 Jan; 8(3):4062-4078. PubMed ID: 27845897
[TBL] [Abstract][Full Text] [Related]
37. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
38. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity.
Pasini D; Bracken AP; Jensen MR; Lazzerini Denchi E; Helin K
EMBO J; 2004 Oct; 23(20):4061-71. PubMed ID: 15385962
[TBL] [Abstract][Full Text] [Related]
39. A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma.
Anestopoulos I; Sfakianos AP; Franco R; Chlichlia K; Panayiotidis MI; Kroll DJ; Pappa A
Molecules; 2016 Dec; 22(1):. PubMed ID: 28042859
[TBL] [Abstract][Full Text] [Related]
40. Loss of maternal EED results in postnatal overgrowth.
Prokopuk L; Stringer JM; White CR; Vossen RHAM; White SJ; Cohen ASA; Gibson WT; Western PS
Clin Epigenetics; 2018 Jul; 10(1):95. PubMed ID: 30005706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
